PT  - JOURNAL ARTICLE
AU  - Lennon, Robert P.
AU  - Small, Meg L.
AU  - Smith, Rachel A.
AU  - Van Scoy, Lauren J.
AU  - Myrick, Jessica G.
AU  - Martin, Molly A.
AU - Data4Action Research Group
TI  - Unique predictors of intended uptake of a COVID-19 vaccine
AID  - 10.1101/2020.12.11.20235838
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.11.20235838
4099  - http://medrxiv.org/content/early/2020/12/14/2020.12.11.20235838.short
4100  - http://medrxiv.org/content/early/2020/12/14/2020.12.11.20235838.full
AB  - Introduction An effective vaccine for COVID-19 is only of value if the public has confidence in taking it. There is little data on COVID-19-specific vaccine confidence or its determinants in the United States. The objective of this study was to determine public confidence in a COVID-19 vaccine.Methods A cross-sectional survey of Pennsylvanian adults, August-October, 2020, to identify their likelihood of taking an approved, no-cost coronavirus vaccine, general vaccine acceptance, and sociodemographic traits to identify predictors of vaccine acceptance.Results Of the 950 respondents, 55% were “very likely”, 20% “somewhat likely”, 14% “unsure”, 4% “somewhat unlikely”, and 7% “very unlikely” to take a coronavirus vaccine, even though 70% had taken the flu vaccine since September 2019. The strongest predictors of vaccine acceptance were trust in the system evaluating vaccines and perceptions of local COVID-19 vaccination norms. The strongest predictors of negative vaccine intentions were worries about unknown side-effects and positive attitudes toward natural infection. Sociodemographic factors, political views, and religiosity did not predict vaccine intentions.Conclusions Fewer adults intend to take a coronavirus vaccine than currently take the flu vaccine. To overcome coronavirus vaccine hesitancy, information campaigns to reinforce positive predictors and overcome negative predictors are indicated.Competing Interest StatementThe authors report no conflicts of interest. Members of the Data4Action Research Group include leaders in each funding source. Those leaders participated in developing the project concept and methodologies and study design. They were not involved in analysis, interpretation of the data, initial writing, or the decision to submit the report for publication.Funding StatementThis research was supported by funding from the Office of the Provost and the Clinical and Translational Science Institute, Huck Life Sciences Institute, and Social Science Research Institutes at the Pennsylvania State University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Pennsylvania State University IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not available at this time.